株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:多発性硬化症の疫学予測

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2026

発行 GlobalData 商品コード 258690
出版日 ページ情報 英文 35 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.42円で換算しております。
Back to Top
EpiCast Report:多発性硬化症の疫学予測 EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2026
出版日: 2017年11月01日 ページ情報: 英文 35 Pages
概要

多発性硬化症(MS)は世界で毎年250万人に影響を与えており、ヤングアダルトにおいては最大の衰弱性神経疾患です。調査対象10ヶ国全体の症例数は 2014年に909,398件と推計され、2024年までに 942,567件に増加すると予測されています。

当レポートでは、多発性硬化症(MS)のリスク因子および世界的動向について調査し、主要8市場(米国、フランス、ドイツ、イタリア、スペイン、英国、日本、カナダ)および新興市場(インド・中国)のデータを提供しております。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • リスク因子と共存症
    • MS患者の家族はMSを発症する1%〜5%のリスクを持つ
    • 女性はMSを発症するリスクが2倍、しかし男性は予後が悪い
    • コーケイジャン(Caucasian)はその他の人種/民族よりもMSリスクが高い
    • MSに対するビタミンDの予防効果は、生まれた地域・月と関連する可能性がある
    • 環境暴露のタイミングがMSリスクに影響を与える
    • 受動喫煙はMSリスクを増加させ、予後を悪化させる可能性がある
    • 自己免疫疾患はMSの共存症となる可能性
    • 精神性共存症はMS患者の最大60%に見られ、再発率に影響を与える可能性がある
  • 世界の動向
    • 北米
    • 欧州
    • アジア
  • 予測手法
    • 利用ソース
    • 利用しなかったソース
    • 予測の前提条件・手法
  • 多発性硬化症の疫学予測
    • 有病数
    • 有病数:年齢別
    • 有病数:性別
    • 発症数
    • 発症数:年齢別
    • 発症数:性別
    • 多発性硬化症のサブタイプ
  • 考察
    • 疫学動向の結論
    • 分析の限界
    • 分析の強み

第4章 付録

  • 参考資料
  • 著者について
  • GlobalDataについて
  • EpiCastについて
  • 免責事項

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER168-17

Multiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination followed by axon damage and paralysis. MS symptoms include muscle weakness, weak reflexes, tremor, muscle spasm, prolonged double vision, slurred speech, and balance problems. It can occur at any age, but commonly affects people of ages 15-60 years. Women are about twice as likely as men to develop this disease (Mayo Clinic, 2016). MS symptoms may occur and disappear completely, while the permanent neurological problems occur when the disease advances.

Our epidemiologists forecast that the diagnosed prevalent cases of MS in the 7MM will grow by an Annual Growth Rate (AGR) of almost 0.8% per year over the next 10 years, from around 1 million cases in 2016 to around 1.1 million cases in 2026. Of the 7MM, the US had the highest number of diagnosed prevalent cases with around 0.4 million cases in 2016, while Japan had the lowest number of diagnosed prevalent cases with almost 20,000 cases in 2016. In 2016, the US accounted for around 40% of all the diagnosed prevalent cases of MS, while Japan accounted for only about 2% of diagnosed prevalent cases of MS in the 7MM.

Our epidemiologists forecast that the diagnosed incident cases of MS in the 7MM will grow by an AGR of around 0.3% per year over the next 10 years, from around 49,000 cases in 2016 to just over 50,000 cases in 2026. Additionally, the US will have the highest AGR of almost 0.8%, while Italy will have the lowest at negative rate of around 0.5%. From the 7MM, the US had the highest number of diagnosed incident cases of MS with over 20,000 cases in 2016, while Japan had the lowest number of diagnosed incident cases of MS with nearly 1,000 cases in 2016. In 2016, the US accounted for over 42% of all the MS cases, while Japan accounted for only about 2% of diagnosed incident cases of MS in the 7MM.

The report "EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and the global and historical trends for MS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed prevalent and diagnosed incident cases of MS, segmented by sex and by age (for all ages) in these markets. The diagnosed prevalent cases are further segmented by types of MS (relapsing-remitting [RRMS], primary progressive [PPMS], and secondary progressive [SPMS]) in the 7MM.

Scope

  • The Multiple sclerosis (MS) EpiCast Report provides an overview of the risk factors and global trends for MS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed prevalent and diagnosed incident cases of MS, segmented by sex and by age (for all ages) in these markets. The diagnosed prevalent cases are further segmented by types of MS (relapsing-remitting [RRMS], primary progressive [PPMS], and secondary progressive [SPMS]) in the 7MM.
  • The MS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The MS EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global MS market.
  • Quantify patient populations in the global MS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MS therapeutics in each of the markets covered.
  • Understand magnitude of MS population by disease type.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Multiple Sclerosis Executive Summary 4

  • 2.1 Related Reports 6
  • 2.2 Upcoming Reports 6

3 Epidemiology 7

  • 3.1 Disease Background 7
  • 3.2 Risk Factors and Comorbidities 7
  • 3.3 Global and Historical Trends 8
  • 3.4 Forecast Methodology 10
    • 3.4.1 Sources 10
    • 3.4.2 Forecast Assumptions and Methods 13
    • 3.4.3 Diagnosed Prevalent Cases of MS 14
    • 3.4.4 Diagnosed Prevalent Cases of MS by Types 17
    • 3.4.5 Diagnosed Incident Cases of MS 19
  • 3.5 Epidemiological Forecast for MS (2016-2026) 21
    • 3.5.1 Diagnosed Prevalent Cases of MS 21
    • 3.5.2 Age-Specific Diagnosed Prevalent Cases of MS 22
    • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of MS 22
    • 3.5.4 Diagnosed Prevalent Cases of MS by Types 23
    • 3.5.5 Diagnosed Incident Cases of MS 24
    • 3.5.6 Age-Specific Diagnosed Incident Cases of MS 25
    • 3.5.7 Sex-Specific Diagnosed Incident Cases of MS 26
  • 3.6 Discussion 27
    • 3.6.1 Epidemiological Forecast Insight 27
    • 3.6.2 Limitation of Analysis 28
    • 3.6.3 Strengths of Analysis 29

4 Appendix 30

  • 4.1 Bibliography 30
  • 4.2 About the Authors 32
    • 4.2.1 Epidemiologist 32
    • 4.2.2 Reviewers 33
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 33
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 34
  • 4.3 About GlobalData 35
  • 4.4 Contact Us 35
  • 4.5 Disclaimer 35

List of Tables

1.1 List of Tables

  • Table 1: Risk Factors and Comorbidities for MS 8
  • Table 2: 7MM, Diagnosed Prevalent Cases of MS, Both Sexes, All Ages, Selected Years 2016-2026 21
  • Table 3: 7MM, Diagnosed Incident Cases of MS, Both Sexes, All Ages, Selected Years 2016-2026 25

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of MS, Both Sexes, All Ages,2016 and 2026 5
  • Figure 2: 7MM, Diagnosed Incident Cases of MS, Both Sexes, All Ages, 2016 and 2026 6
  • Figure 3: 7MM, Age-Standardized Diagnosed Prevalence of MS (%), Both Sexes, All Ages, 2016 9
  • Figure 4: 7MM, Age-Standardized Diagnosed Incidence of MS (Cases per 100,000 Population), Both Sexes, All Ages, 2016 10
  • Figure 5: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of MS 11
  • Figure 6: 7MM, Sources Used and Not Used, Diagnosed Incident Cases of MS 12
  • Figure 7: 7MM, Sources Used and Not Used for the Diagnosed Prevalent Cases of MS by Types 13
  • Figure 8: 7MM, Age-Specific Diagnosed Prevalent Cases of MS, Both Sexes, All Ages, 2016 22
  • Figure 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of MS, Both Sexes, All Ages, 2016 23
  • Figure 10: 7MM, Diagnosed Prevalent Cases of MS by Types, Both Sexes, All Ages, 2016 24
  • Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of MS, Both Sexes, All Ages, 2016 26
  • Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of MS, Both Sexes, All Ages, 2016 27
Back to Top